Italia markets closed

Affimed N.V. (0HL9.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
5,42+0,02 (+0,41%)
Alla chiusura: 05:54PM GMT

Affimed N.V.

Technologiepark
Im Neuenheimer Feld 582
Heidelberg 69120
Germany
49 6221 6743 60
https://www.affimed.com

Settore/i
Settore
Impiegati a tempo pieno219

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Andreas Harstrick M.D.Interim CEO, Chief Medical Officer & Member of Management Board535,09kN/D1961
Dr. Wolfgang FischerMD, COO & Member of Management Board645,58kN/D1964
Ms. Denise MuellerChief Business Officer & Member of Management Board628,24kN/D1970
Prof. Melvyn LittleFounder & ConsultantN/DN/DN/D
Mr. Michael WolfHead of Finance & AdministrationN/DN/D1967
Mr. Alexander FudukidisHead of Investor Relations & Director of Investor RelationsN/DN/DN/D
Mary Beth SandinVice President of Marketing & CommunicationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Governance aziendale

L'ISS Governance QualityScore di Affimed N.V. al 1 marzo 2024 è 6. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 4; diritti degli azionisti: 3; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.